Previous studies have shown that erythropoietin (EPO) is neuroprotective in both in vivo and in vitro models of hypoxia ischemia. However these studies hold limited clinical translations because the underlying mechanism remains unclear and the key molecules involved in EPO-induced neuroprotection are still to be determined. This study investigated if tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and its upstream regulator signaling molecule Janus kinase-2 (JAK-2) are critical in EPO-induced neuroprotection. Hypoxia ischemia (HI) was modeled in-vitro by oxygen and glucose deprivation (OGD) and in-vivo by a modified version of Rice-Vannucci model of HI in 10-day-old rat pups. EPO treated cells were exposed to AG490, an inhibitor of JAK-2 or TIMP-1 neutralizing antibody for 2 h with OGD. Cell death, phosphorylation of JAK-2 and signal transducers and activators of transcription protein-3 (STAT-3), TIMP-1 expression, and matrix metalloproteinase-9 (MMP-9) activity were measured and compared with normoxic group. Hypoxic ischemic animals were treated one hour following HI and evaluated 48 h after. Our data showed that EPO significantly increased cell survival, associated with increased TIMP-1 activity, phosphorylation of JAK-2and STAT-3, and decreased MMP-9 activity in vivo and in vitro. EPO's protective effects were reversed by inhibition of JAK-2 or TIMP-1 in both models. We concluded that JAK-2, STAT-3 and TIMP-1 are key mediators of EPO-induced neuroprotection during hypoxia ischemia injury.
Introduction
Asphyxia is the disruption of placental/pulmonary gas exchange. It is associated with hypoxemia, respiratory and systemic acidosis, which are linked to cerebral hypoxia ischemia in neonates (Vannucci, 2000) . Erythropoietin (EPO), a hematopoietic growth factor, with non-hematopoietic functions, is upregulated during hypoxia ischemia in the brain of most mammals (Prass et al., 2003) . Although the upregulation of endogenous EPO is not enough to confer neuroprotection during hypoxia, it is able to turn on some of the necessary prosurvival pathways (Shein et al., 2008) . Previous studies have shown that exogenous administration of EPO confers neuroprotection in both in vitro and in vivo models of cerebral ischemia (Brines et al., 2000; Sakanaka et al., 1998; Sun et al., 2005) . Our understanding of the mechanism by which this occurs is still unfolding. Physiologically, EPO binds to the EPO receptor (EPOR) and promotes cellular differentiation, proliferation and inhibition of apoptosis (Brines et al., 2000; Sakanaka et al., 1998; Sun et al., 2005) . It also prevents damage against mechanical trauma, excitotoxins, and neuro-inflammation (Brines et al., 2000; Sakanaka et al., 1998; Sun et al., 2005) .
Previous studies have shown that EPO and other hematopoietic growth factors are associated with the Janus kinase-2 (JAK-2), a tyrosine kinase (Harpur et al., 1992; Witthuhn et al., 1993) . Janus kinases are a family of receptor tyrosine kinases associated with membrane receptors and are phosphorylated when a specific ligands bind to its receptor. JAK-2 kinases phosphorylate cytosolic transcription factors, signal transducers and activators of transcription (STAT), allowing for the transcription of proteins such as: cytokines, growth factors, cell survival and differentiation factors depending on the ligand (Ihle, 1995b (Ihle, , 1995a Shuai et al., 1992; Kaplan et al., 1996) . STAT-3 and STAT-5 are both associated with the EPOR and are both activated by the binding of EPO to its receptor (Ruscher et al., 2002; Toth et al., 2008) . STAT-3 is not as well studied as the other EPO activated STATs. However some earlier findings show that STAT-3 can bind to the promoter sequence of the tissue inhibitor of matrix metalloproteinase (TIMP) -1 gene (Bugno et al., 1995 , Dominguez et al., 2008 . TIMP-1 is associated with erythroid cell survival, growth 
